在心力衰竭中免疫调节和免疫药理学
George Markousis-Mavrogenis1, Lukas Baumhove1, Ali A Al-Mubarak1
1Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Nature reviews. Cardiology
|September 14, 2023
概括
免疫系统在心力衰竭中起着关键作用,但在治疗上未得到充分利用. 了解当前的心力衰竭治疗如何影响免疫力,对于开发新的免疫调节疗法至关重要.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫系统是心力衰竭发展和进展的组成部分.
- 目前的心力衰竭治疗具有显著的,往往被忽视的免疫调节效应.
- 在心力衰竭中准免疫系统的治疗潜力在很大程度上仍未得到开发.
研究的目的:
- 审查已知心力衰竭治疗的免疫调节效应.
- 为开发心力衰竭的新型免疫调节疗法提供框架.
- 确定心力衰竭中免疫调节的患者亚群和未来的治疗点.
主要方法:
- 对现有的基于证据的心力衰竭治疗方法及其对免疫系统的影响进行了全面的文献审查.
- 分析已完成和正在进行的临床试验,调查心力衰竭的免疫调节疗法.
- 确定潜在的未来治疗目标和研究方向.
主要成果:
- 基于证据的心力衰竭疗法具有超出其主要机制的多种免疫调节作用.
- 特定的患者群体可能会从免疫调节干预中获得更大的益处.
- 确定了几个有前途的免疫调节标和正在进行的临床试验.
结论:
- 更深入地了解治疗诱导的免疫调节对于优化心力衰竭护理至关重要.
- 利用现有疗法的免疫效应和探索新型免疫调节剂可以推进心力衰竭治疗.
- 未来的研究应该专注于针对心力衰竭患者的个性化免疫调节策略.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
460
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
Heart Failure Drugs: Inotropic Agents
617
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
617
Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16


